Gainers & Losers Of The Day: ATOS, APOP, TSRO, GALE, ACUR...

(RTTNews) - The following are some of the biotech stocks that made their way onto the Day's Gainers & Losers' list of February 8, 2017.

GAINERS

1. Atossa Genetics Inc. (ATOS)

Gained 20.98% to close Wednesday's (Feb.8) trading at $1.73. The stock was up more than 11% in after-hours.

News: No news

Near-term catalyst:

The company's lead product candidate is Fulvestrant. A phase II study of Fulvestrant administered with patented microcatheters in patients with ductal carcinoma in situ or breast cancer who are scheduled for lumpectomy or mastectomy, is underway. The study is expected to be fully enrolled by August of this year.

2. Cellect Biotechnology Ltd. (APOP)

Gained 18.94% to close Wednesday's trading at $4.96.

News: The first blood cancer patient in the company's recently initiated phase I/II trial of its stem cell technology ApoGraft has been treated.

The company's ApoGraft process is designed to prevent Graft-versus-Host Disease (GvHD), a common complication associated with stem cell transplant.

Near-term catalyst:

Definitive and complete results from a trial of ApoGraft process in healthy volunteers are expected before the end of this quarter (Q1, 2017).

3. Cerulean Pharma Inc. (CERU)

Gained 14.66% to close Wednesday's trading at $1.33.

News: No news

Near-term catalyst:

On February 1, 2017, Cerulean announced it is evaluating potential alternatives such as the sale of the company, a merger, a business combination, a strategic investment into the company, or a sale, license or disposition of assets of the company to maximize stockholder value.

4. ContraVir Pharmaceuticals Inc. (CTRV)

Gained 13.29% to close Wednesday's trading at $1.62.

News: No news

Anticipated event: An overview of the company's business is to be presented at BIO CEO & Investor Conference on February 13, 2017.

Cerulean's most advanced investigational drug is Valnivudine, which is under a phase III trial to reduce the incidence of shingles pain and post-herpetic neuralgia.

5. Tesaro Inc. (TSRO)

Gained 12.11% to close Wednesday's trading at $182.68.

News: The company has received takeover interest, reported Reuters

Founded in 2010, TESARO went public on June 28, 2012, offering its shares at a price of $13.50 each. The stock touched an all-time high of $190 on Wednesday, before closing the day's trading at $182.68.

LOSERS

1. Galena Biopharma Inc. (GALE)

Lost 40.46% to close Wednesday's trading at $0.83.

News: The company has priced its underwritten public offering of units - with each unit consisting of one full share of its common stock and a warrant to purchase one share of its common stock, and is priced at $1.00 per unit.

The warrants are immediately exercisable at a price of $1.10 per share of common stock and will expire on the fifth anniversary of the date of issuance. The offering is expected to close on or about February 13, 2017, subject to customary closing conditions.

2. Acura Pharmaceuticals Inc. (ACUR)

Lost 29.23% to close Wednesday's trading at $0.92.

News: No news

Recent event: On February 3, 2017, the company filed S-1 registration to raise $5 million.

3. Second Sight Medical Products Inc. (EYES)

Lost 27.54% to close Wednesday's trading at $2.00

Pullback after yesterday's (Feb.7th) gain of over 78%.

Anticipated events:

- The record date for the company's rights offering is February 10, 2017 - Q4 and full-year 2016 financial results to be reported on March 1, 2017.

Near- term catalyst:

The first human implant of the Orion I Visual Cortical Prosthesis will be performed in the first half of this year.

Orion I is an investigational device for restoring some vision to individuals who are blind due to causes other than preventable or treatable conditions.

4. Moleculin Biotech Inc. (MBRX)

Lost 16.67% to close Wednesday's trading at $1.50. The stock has lost 25% of its value over the last 2 days.

News: No news

Near-term catalyst: Report data from phase II trial evaluating Annamycin as a potential treatment for relapsed or refractory acute myeloid leukemia by the second half of 2017.

5. MYOS RENS Technology Inc. (MYOS)

Lost 12.71% to close Wednesday's trading $4.12.

Pullback after yesterday's gain of over 30%.

News: No news

MYOS RENS is the developer of muscle-health ingredient Fortetropin, the first clinically-proven, all natural myostatin-reducing agent. Fortetropin is the active ingredient in Re Muscle Health, a line of non-GMO protein bars, shakes, pudding mixes and powders that was launched in March 2015.